Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016’, provides in depth analysis on Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted pipeline therapeutics.

The report provides comprehensive information on the Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
  
• The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report reviews key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics and enlists all their major and minor projects
  
• The report assesses Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report summarizes all the dormant and discontinued pipeline projects
  
• The report reviews latest news and deals related to Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand the targeted therapy areas and indications for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
  
• Identify the use of drugs for target identification and drug repurposing
  
• Identify potential new clients or partners in the target demographic
  
• Develop strategic initiatives by understanding the focus areas of leading companies
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) development landscape
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Overview 7
Therapeutics Development 8
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Stage of Development 8
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Therapy Area 9
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Indication 10
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Companies 13
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Universities/Institutes 15
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Princeton University 23
Takeda Pharmaceutical Company Limited 24
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Drug Profiles 25
ABT-737 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
AT-101 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
navitoclax dihydrochloride - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
rottlerin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
WEHI-539 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Dormant Projects 38
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Discontinued Products 42
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Featured News & Press Releases 43
Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539 43
Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting 43
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting 44
Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting 46
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting 47
May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting 47
Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer 47
Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer 48
Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology 49
Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia 50
Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting 51
Dec 12, 2005: Ascenta AT-101 Data Presented At The American Society Of Hematology 47th Annual Meeting And Exposition In Atlanta, Georgia 52
Dec 12, 2005: Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia 53
Nov 18, 2005: Ascenta AT-101 Clinical Trial Data Presented At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer 54
Nov 10, 2005: Phase II Program Of Ascenta''s Lead Product, AT-101, A Pan-inhibitor Of The Bcl-2 Protein Family, Begins 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by AbbVie Inc., H1 2016 22
Pipeline by Princeton University, H1 2016 23
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24
Dormant Projects, H1 2016 38
Dormant Projects (Contd..1), H1 2016 39
Dormant Projects (Contd..2), H1 2016 40
Dormant Projects (Contd..3), H1 2016 41
Discontinued Products, H1 2016 42

List of Figures

Number of Products under Development for, H1 2016 8
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Actions, H1 2016 18
Number of Products by Molecule Types, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 20